YTS109 clinical trials
How each study uses YTS109 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the YTS109 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
11 studies that test it; most in 2025 (9)
| Year | Studies |
|---|---|
| 2025 | 9 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 3
China Immunotech (Beijing) Biotechnology Co., Ltd. (8) · Institute of Hematology & Blood Diseases Hospital, China (1) · Children's Hospital of Fudan University (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test YTS109.
- Nov 2026Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesPhase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Nov 2026An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesPhase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Dec 2026A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaPhase 1 · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- Mar 2027YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesPhase 1 · Children's Hospital of Fudan University
- Mar 2027Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic AnemiaPhase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
- May 2027A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesPhase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
- Jun 2027A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaPhase 1 · Institute of Hematology & Blood Diseases Hospital, China
- Aug 2027A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesPhase 1 · China Immunotech (Beijing) Biotechnology Co., Ltd.
Studies
Open first, then newest update. How each study uses YTS109 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07453836Written as YTS109 cell
- A Clinical Study of YTS109 Cell in R/R Autoimmune DiseasesRecruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT06978647Written as YTS109 cell
- A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune DiseasesRecruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07123519Written as YTS109 cell
- A Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07104721Written as YTS109 cell
- An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune DiseasesRecruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07236762Written as YTS109 cell
- Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune DiseasesRecruitingPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07236801Written as YTS109 cell
- YTS109 in Pediatric Relapsed/Refractory Autoimmune DiseasesNot yet recruitingPhase 1Children's Hospital of Fudan UniversityNCT07439029Written as YTS109 cell
- A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaNot yet recruitingPhase 1Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07287930Written as YTS109 cell
- A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaActive, not recruitingPhase 1Institute of Hematology & Blood Diseases Hospital, ChinaNCT06770504Written as YTS109
- A Clinical Study of YTS109 Cell in R/R Systemic Lupus ErythematosusTerminatedPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT06943937Written as YTS109 cell injection
- A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic AnemiaCompletedPhase 1China Immunotech (Beijing) Biotechnology Co., Ltd.NCT07075484Written as YTS109 cell